10 Nugent Road
Surrey Research Park
100 articles about ReNeuron
ReNeuron Signs New Exosome Research Collaboration
ReNeuron Group plc announced that it has signed a new research evaluation agreement with a major U.S. biotechnology company in connection with the use of the Company's proprietary exosomes for the delivery of novel gene silencing therapeutics.
ReNeuron Provides Program and Regulatory Approvals Update
ReNeuron Group plc, a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programs.
ReNeuron Announces CTX Cell Line Shows Further Potential
Newly Published Positive Efficacy Data in an Accepted Model of Huntington's Disease
ReNeuron Announces Exosome Research Collaboration
ReNeuron Group plc announced that it has signed a research agreement with an unnamed major pharmaceutical company to explore the potential use of the Company's proprietary exosomes to deliver novel therapeutics.
ReNeuron Update Regarding COVID-19
ReNeuron Group plc, a global leader in the development of cell-based therapeutics, provides the following update in light of the COVID-19 pandemic and the effect on the Company of U.K. and U.S. government measures to contain the spread of the disease..
ReNeuron Announces Publication of Positive Phase 2a Stroke Clinical Data
ReNeuron Group plc, a global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase 2a clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke.
ReNeuron Presents Positive Data at the 27th Annual Congress of the European Society of Gene and Cell Therapy on Lead Cell Line
New data show ReNeuron's lead CTX cell therapy candidate can be re-programmed into a pluripotent state and differentiated into other cell types
Clinical Catch-Up: October 14-18
10/21/2019Last week was busy for clinical trial news. Here’s a look.
ReNeuron Presents Positive Clinical Data at the American Academy of Ophthalmology Annual Meeting
Study investigator presents positive efficacy data in ongoing retinal disease clinical trial
ReNeuron Announces Clinical Update and Conference Presentations
"Clear efficacy signal" in Phase 2a study of hRPC cell therapy in retinitis pigmentosa
ReNeuron Expands Exosome IP Portfolio with Key Patent Grants
ReNeuron Group plc, a UK-based global leader in the development of cell-based therapeutics, announced that it has expanded its intellectual property estate via the grant of a number of key patents covering its exosome technology platform.
ReNeuron to Participate in the Jefferies 2019 Global Healthcare Conference
ReNeuron Group plc announced that ReNeuron's management team will participate in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 in New York City.
ReNeuron Provides Business Update and Results Notification
Second Cohort of Phase 2a Study in Retinitis Pigmentosa Dosing Complete
ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Study at the Sixth Annual Retinal Cell and Gene Therapy Innovation Summit
hRPC Cell Therapy Demonstrates Sustained and Further Improvement in Vision at 60 and 120 Days in First Cohort of Phase 2a study in Retinitis Pigmentosa
ReNeuron Partners with Fosun Pharma in China
ReNeuron to receive upfront, near term and estimated success-based milestone payments of £80.0 million (US$104.8 million) and double-digit royalties on sales
ReNeuron to Present at the H.C. Wainwright Global Life Sciences Conference
ReNeuron Group plc announced that Olav Hellebø, the Company's Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 3:30 p.m. BST at the Grosvenor House in London.
ReNeuron to Present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day
ReNeuron Group plc announced that Olav Hellebø, the Company's Chief Executive Officer, will present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day on Thursday, March 21, 2019 at 9:10 am ET at The Metropolitan Club in New York City.
ReNeuron Announces Retinal Clinical Trial Progresses to Next Stage
ReNeuron Group plc is pleased to announce a further update on progress with the ongoing Phase I/II clinical trial in the US of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).
ReNeuron Group plc Announces Positive Preliminary Data in U.S. Retinitis Pigmentosa Trial
hRPC Cell Therapy Demonstrates Significant Restoration of Vision in First Cohort of Phase 2 Study in Retinitis Pigmentosa
ReNeuron Release: Reports Positive Results In Phase II Stroke Trial